Related by context. All words. (Click for frequent words.) 75 chronic HCV infection 70 HBeAg negative 70 chronic HCV genotype 70 CCR5 tropic HIV 70 chronic HBV 69 HCV genotype 1 68 HCV infection 68 hepatitis C HCV 68 stage IIIB 67 hepatitis C genotype 67 chronic HBV infection 67 relapsed MM 67 HBeAg positive 67 interferon ribavirin 66 chronic hepatitis C 66 recurrent genital herpes 66 metastatic malignant melanoma 66 HCV infections 66 herpes zoster shingles 66 leukemia AML 66 superficial bladder cancer 65 ribavirin RBV 65 symptomatic BPH 65 unresectable stage 65 CCR5 tropic 65 mRCC 65 Pemetrexed 65 ribavirin therapy 65 treatment naive genotype 65 relapsed ovarian cancer 65 prostate cancer CRPC 65 PREZISTA r 65 candidemia 65 minimally symptomatic 65 relapsing remitting MS RRMS 65 Peg IFN 65 NRTI resistance 65 recurrent glioblastoma multiforme 65 HCV infected 64 autoantibody positive 64 invasive candidiasis 64 CYT# potent vascular disrupting 64 treatment naïve genotype 64 Hepatitis C virus HCV 64 hepatitis B HBV 64 ceftazidime 64 CHOP chemotherapy 64 bendamustine 64 metastatic bladder 64 T2DM 64 CCR5 antagonist 64 HCV SPRINT 64 invasive aspergillosis 64 castrate resistant prostate cancer 64 grade cervical intraepithelial 63 remission induction 63 peginterferon 63 KRAS mutations occur 63 nonsmall cell lung cancer 63 naive HCV 63 acute GvHD 63 relapsed leukemia 63 pancreatic NET 63 C. trachomatis 63 micafungin 63 esophageal candidiasis 63 alkylating agent 63 fallopian tube carcinoma 63 cutaneous T 63 null responder HCV 63 docetaxel Taxotere ® 63 HCV genotype 63 Gleevec resistant 63 de novo kidney transplant 63 taxane resistant 63 metastatic RCC 63 recurrent NSCLC 63 terlipressin 63 acute myelogenous leukemia AML 63 taxane chemotherapy 63 naïve HCV 63 protease inhibitor PI 63 immunocompetent 63 Hepatitis C HCV 63 Acute Coronary Syndromes ACS 63 non metastatic osteosarcoma 63 recurrent glioblastoma 63 rituximab refractory 63 recurrent metastatic 63 OHR/AVR# 63 Fludara 63 nosocomial pneumonia 63 pediatric acute lymphoblastic 62 pegylated interferon alpha 62 forodesine 62 reduce serum phosphate 62 leukemia CLL 62 androgen independent 62 HCV genotypes 62 recurrent malignant glioma 62 medullary thyroid cancer 62 posaconazole 62 coinfected 62 chronic hepatitis B. 62 castrate resistant 62 latent tuberculosis infection 62 lupus nephritis 62 nucleoside analog 62 NATRECOR ® 62 oral vancomycin 62 AGILECT R 62 posterior uveitis 62 chemotherapy induced neutropenia 62 minimally symptomatic metastatic castrate 62 amphotericin B 62 nucleoside analogue 62 pegylated interferon alfa 2a 62 Albuferon TM 62 R5 tropic 62 antiretroviral naïve 62 CMV disease 62 overactive bladder syndrome 62 Reverset 62 sustained virologic response 62 decompensated liver disease 62 Velcade bortezomib 62 non splenectomized 62 refractory CLL 62 chronic ITP patients 62 virologic failure 62 VFEND 62 Viramidine 62 LTBI 62 intravenous bisphosphonates 62 anthracycline containing 62 relapsed ALL 62 Allovectin 7 ® 62 BARACLUDE ® 62 pegylated alpha interferon 62 hepatitis C virus 62 alfa 2a 62 pegylated interferons 62 chronic Hepatitis B 62 oropharyngeal candidiasis OPC 62 pediatric malignancies 62 CMV infection 62 Omacetaxine 62 relapsed multiple myeloma 62 Traficet EN 62 canakinumab 62 chronic hepatitis C. 62 metastatic hormone refractory 62 pegIFN 61 heavily pretreated 61 oral prodrug 61 genital HSV 61 AEG# 61 ritonavir boosted 61 lenalidomide Revlimid R 61 leukemia ALL 61 idarubicin 61 unresectable 61 severe oral mucositis 61 vinorelbine 61 nucleotide analogue 61 metastatic neuroendocrine tumors 61 pheochromocytoma 61 IV metastatic melanoma 61 LHRH receptor positive 61 carcinoid syndrome 61 tigecycline 61 TKI therapy 61 Tindamax R 61 immunocompetent patients 61 dacarbazine 61 Zavesca R 61 Amgen Neulasta R 61 gemcitabine Gemzar ® 61 Hepatocellular Carcinoma HCC 61 eosinophilic asthma 61 mildly symptomatic 61 invasive fungal infection 61 gemcitabine carboplatin 61 FluCAM arm 61 antiretroviral naive 61 BCG refractory 61 visilizumab 61 gemcitabine Gemzar 61 hyperphenylalaninemia HPA due 61 colorectal liver metastases 61 chronically infected 61 severe neutropenia 61 interferon alfa 2a 61 relapsed AML 61 relapsed refractory multiple myeloma 61 atherothrombotic events 61 HCV RESPOND 2 61 CLL SLL 61 5-FU/LV 61 evaluating tivozanib 61 HuLuc# 61 PAOD 61 GnRH agonists 61 prostate cancer CaP 61 PRTX 61 metastatic gastric 61 nitazoxanide 61 Pegasys plus Copegus 61 novel VDA molecule 61 Opportunistic infections 61 HeFH 61 cell lymphoma CTCL 61 metastatic renal cell carcinoma 61 Copegus ribavirin 61 meropenem 61 castration resistant prostate cancer 61 Pegylated Interferon 61 HPV subtypes 61 Infusion Reactions Severe 61 abacavir Ziagen 61 salmeterol fluticasone 61 hypereosinophilic syndrome 61 metastatic castration resistant 61 Peginterferon alfa 2b 61 FLT3 mutations 61 ritonavir boosted protease inhibitor 61 histologies 61 H pylori 61 receptor tyrosine kinase inhibitor 61 HCV 61 recurrent bladder 61 hepatitis B virus HBV 61 SCIg 61 ano genital warts 61 daptomycin 61 osteosarcomas 61 nucleotide analog 61 relapsed SCLC 61 corticosteroid dexamethasone 61 indolent NHL 61 Pegasys peginterferon alfa 2a 61 thetreatment 61 voriconazole 61 pegylated interferon alfa 61 refractory gout 61 valopicitabine 60 virus HCV infection 60 refractory cutaneous T 60 PD LID 60 IV melanoma 60 androgen deprivation 60 refractory NSCLC 60 diabetes mellitus DM 60 phase IIb study 60 basal cell nevus syndrome 60 TMP SMX 60 metastatic lung cancer 60 somatostatin analogues 60 hepatitis C virus HCV 60 NOMID 60 Amigal 60 tenofovir emtricitabine 60 pegylated interferon 60 Primary IGFD 60 cIAI 60 budesonide foam 60 null responder 60 advanced hepatocellular carcinoma 60 Aspergillus infections 60 smoldering multiple myeloma 60 IV NSCLC 60 metastatic renal cell 60 NRTI backbone 60 seropositive patients 60 pancreatic insufficiency 60 hepatitis B infection 60 acute STEMI 60 Diabetic Macular Edema 60 refractory chronic myeloid 60 elvucitabine 60 SJIA 60 bacteriuria 60 MAGE A3 ASCI 60 abacavir lamivudine 60 symptomatic benign prostatic 60 stage IIIB IV 60 sorafenib Nexavar 60 candidiasis 60 MyVax ® 60 Ophena TM 60 refractory ovarian cancer 60 immuno compromised patients 60 ABSSSI 60 CTAP# Capsules 60 KRAS mutant tumors 60 null responders 60 combination antiretroviral therapy 60 secondary hyperparathyroidism 60 metastatic malignant 60 OncoVEX GM CSF 60 achieve sustained virologic 60 bexarotene 60 genital herpes infections 60 Nilotinib 60 refractory AML 60 resectable 60 acne vulgaris 60 chronic periodontitis 60 ketolide antibiotic 60 MALT lymphoma 60 DU #b 60 mycosis fungoides 60 acute leukemias 60 benign prostatic hypertrophy 60 Helicobacter pylori eradication 60 dacarbazine DTIC 60 Fludarabine 60 doxorubicin HCl liposome injection 60 prostate cancer HRPC 60 elevated LDL cholesterol 60 TYZEKA 60 CMV retinitis 60 weekly subcutaneous injections 60 relapsed CLL 60 severe hypercholesterolemia 60 TYGACIL 60 carcinoids 60 HIV HCV coinfected 60 prostate carcinoma 60 PegIFN RBV 60 IV bisphosphonates 60 biologic DMARD 60 Staphylococcus aureus infections 60 HGS ETR1 60 calcineurin inhibitors 60 anti angiogenic agents 60 pegfilgrastim 60 caspofungin 60 Pegasys ® 60 pancreatic neuroendocrine tumors 60 Chronic lymphocytic leukemia 60 cirrhosis liver failure 60 M#V mutation 60 situ CIS 60 lymphocytosis 60 Surgical resection 60 hepatorenal syndrome 60 haematologic 60 HGS ETR1 mapatumumab 60 concomitant antibiotics 60 metaglidasen 60 hemorrhagic cystitis 60 IBS C 60 dapsone 60 peginterferon alpha 2a 60 CIMZIA ™ 60 virological response 60 HBeAg positive patients 60 Recombinant interferon alpha 60 doublet chemotherapy 60 Sudhir Agrawal D.Phil 60 verteporfin 60 benign prostatic hypertrophy BPH 60 systemic ALCL 60 genotypic resistance 60 paroxysmal AF 60 peginterferon alfa 2b 60 NNRTI resistance 60 cilengitide 60 post herpetic neuralgia PHN 60 interferon alfa 2b 60 TNF antagonist 60 basal cell carcinoma BCC 60 SCCHN 60 NYHA Class II 60 RRMS patients 60 liver metastases 60 Altastaph 60 sorafenib tablets 60 chemoradiotherapy 60 docetaxel chemotherapy 60 anemia neutropenia 60 histologically confirmed 60 COPEGUS ribavirin 60 S. aureus infections 60 lomitapide 60 completely resected 60 AZT zidovudine Retrovir 60 selective modulator 60 lintuzumab SGN 60 trastuzumab Herceptin R 60 chronic hepatitis B 60 naive HCV genotype 60 evaluable subjects 60 Chronic Myelogenous Leukemia CML 60 administered subcutaneously 60 nucleoside analogues 60 essential thrombocythemia ET 60 APTIVUS r 60 Non Hodgkin 60 antibody MAb 60 herpetic keratitis 60 peginterferon alfa 60 miconazole Lauriad ® 60 latent TB infection 60 lumiliximab 60 SPRYCEL ® 60 keloid scarring 59 tuberculin skin testing 59 Sezary syndrome 59 sustained virological response 59 nonalcoholic steatohepatitis NASH 59 generation purine nucleoside 59 PNP inhibitor 59 BRIM2 59 immunomodulatory therapy 59 rilpivirine 59 investigational monoclonal antibody 59 hormone deprivation 59 diabetic kidney 59 liposomal amphotericin B 59 ACZ# 59 Elotuzumab 59 unresectable tumors 59 mcg albinterferon alfa 2b 59 thromboembolic complications 59 refractory APL 59 interferon gamma 1b 59 piperacillin tazobactam 59 superficial basal cell carcinoma 59 ALI ARDS 59 small lymphocytic lymphoma 59 Plicera 59 papillary renal cell carcinoma 59 cSSSIs 59 Combination therapy 59 ADHF 59 CIN3 59 hormone refractory metastatic prostate 59 biliary tract cancer 59 Doxil ® 59 uric acid lowering 59 untreated AML 59 imipenem 59 ZYVOX 59 AVODART 59 INVANZ 59 PROSTVAC VF 59 docetaxel Taxotere R 59 dose cohort 59 Squamous 59 ApoE4 allele 59 Gemzar ® 59 lenalidomide dexamethasone 59 chronic hepatitis cirrhosis 59 NNRTI resistant virus 59 GISTs 59 unresectable recurrent 59 cytoreduction 59 interferon alfa 59 Xanafide 59 cabazitaxel 59 Chronic Idiopathic Constipation 59 ethambutol 59 T1DM 59 metformin sulfonylurea 59 immunosuppressive therapies 59 vWD 59 immunosuppressed 59 VZV 59 Alinia 59 chronic hepatitis 59 standard chemotherapy regimen 59 Severe Primary IGFD 59 adjuvant tamoxifen 59 lymphoid malignancies 59 cervical lesions 59 oral deforolimus 59 pain palliation 59 octreotide 59 Gleevec imatinib mesylate 59 Hodgkin lymphoma HL 59 Toxicities 59 AA Amyloidosis 59 velafermin 59 idiopathic thrombocytopenic purpura 59 multiple myeloma MM 59 hepatitis C infection 59 HIV uninfected 59 HIV seropositive 59 KRAS wild 59 de novo AML 59 DLBCL 59 ceftriaxone 59 FOLFOX6 59 TACI Ig 59 Lupus nephritis 59 Vaprisol 59 colorectal adenoma 59 oropharyngeal candidiasis 59 hemodialysis patients 59 K ras mutations 59 previously untreated follicular 59 estramustine 59 hormone refractory 59 coinfected patients 59 Daclizumab 59 Aflibercept 59 Isentress raltegravir 59 non resectable metastatic 59 CTAP# 59 RhuDex ® 59 DEB# 59 precancerous cervical lesions 59 anagrelide 59 interferon therapy 59 sodium stibogluconate 59 Stage IIB 59 virologically 59 hematopoietic cancers 59 varicella zoster virus VZV 59 dirucotide MBP# 59 opioid induced constipation OIC 59 inhibitor RG# 59 HBeAg + 59 Chronic Hepatitis C 59 Moxifloxacin 59 seronegative 59 noninfectious uveitis 59 pancreatic adenocarcinoma 59 lapatinib Tykerb 59 gemcitabine chemotherapy 59 tamoxifen Nolvadex ® 59 antimuscarinic 59 azacitidine 59 BRAF V# mutation 59 recurrent VTE 59 refractory multiple myeloma 59 onychomycosis 59 HNSCC 59 Phase #/#a trial 59 octreotide LAR 59 tipranavir ritonavir 59 clinically evaluable 59 allogeneic HSCT 59 SHPT 59 follicular lymphoma FL 59 clade B 59 resistant hormone refractory 59 intra arterial chemotherapy 59 UPLYSO 59 imatinib Gleevec 59 Octreolin 59 NMIBC 59 radezolid 59 oral FTY# 59 TNF blocker therapy 59 Hydroxyurea 59 adalimumab Humira 59 operable breast cancer 59 refractory metastatic colorectal cancer 59 Telbivudine 59 Telintra 59 hematologic disorders 59 G#DT 59 H. pylori eradication 59 antithymocyte globulin 59 pomalidomide 59 simplex virus 59 subependymal giant cell 59 systemic fungal infections 59 hoFH 59 cisplatin chemotherapy 59 pyrimethamine 59 malignant ascites 59 Proxinium TM 59 anthracycline taxane 59 HBeAg negative chronic hepatitis 59 dasatinib Sprycel 59 omega interferon 59 nonmelanoma skin cancers 59 lamivudine refractory patients 59 external genital lesions 59 systemic juvenile idiopathic 59 peritumoral brain edema 59 CIPN 59 adult chronic ITP 59 viral kinetics 59 immune thrombocytopenic purpura ITP 59 HIV coinfected 59 bronchogenic carcinoma 59 malignant neoplasms 59 chlamydial infections 59 dasatinib Sprycel ® 59 chronic GVHD 59 therapeutic regimens 59 pentoxifylline 59 paclitaxel Taxol ® 59 neutropenic fever 59 Phase IIb clinical trials 59 cidofovir 59 Actinic Keratosis 59 Pegylated interferon 59 Rimantadine 59 chronic lymphocytic leukemia CLL 59 underwent resection 59 endometrial hyperplasia 59 pamidronate 59 elevated triglyceride levels 59 intestinal metaplasia 59 patients undergoing percutaneous 59 follicular lymphomas 59 orally administered inhibitor 59 vicriviroc 59 daclizumab 59 dopaminergic therapy 59 nephrotoxicity 59 squamous cell lung cancer 59 celgosivir 59 hereditary deficiency 59 toenail onychomycosis 59 Hurthle cell 59 ug dose 59 genotype 1b 59 hepatocellular carcinoma HCC 59 gastrointestinal stromal tumors 59 alemtuzumab treated 59 skeletal metastases 59 Gleevec imatinib 59 antiangiogenic therapy 59 mapatumumab 59 urothelial bladder cancer 59 trans retinoic acid ATRA 59 administered concomitantly 59 HQK 59 LymphoStat B belimumab 59 hypercalcemia 59 evaluating picoplatin 59 efalizumab 59 vaginal candidiasis 59 non squamous NSCLC 59 Hycamtin ® 59 stable angina 59 post herpetic neuralgia 59 glucocorticoid induced osteoporosis 59 taxane refractory 59 atypical hemolytic uremic syndrome 59 refractory chronic lymphocytic 59 immunosuppressed patients 59 indinavir 59 aciclovir 59 pneumococci 59 ISTODAX 58 peritoneal cancer 58 epithelial tumors 58 indolent follicular non 58 anogenital warts 58 trastuzumab Herceptin ® 58 erlotinib Tarceva ® 58 HoFH 58 temsirolimus 58 Amgen Neulasta ® 58 CCR5 mAb 58 gefitinib Iressa 58 hepatocellular cancer 58 T#I mutation 58 venous ulcers 58 Hepatitis B virus HBV 58 mutated KRAS 58 Asymptomatic 58 herpes labialis 58 hepatic metastases 58 Myelodysplastic Syndrome MDS 58 Ribavirin causes 58 Dacogen injection 58 lymphoma CTCL 58 HBV vaccine 58 Arcalyst 58 HuMax EGFr 58 S. aureus bacteremia 58 raltegravir 58 rilonacept 58 chlamydial 58 virologic suppression 58 #mg BID [001] 58 APTIVUS 58 weekly intravenous infusions 58 mycophenolate mofetil 58 adefovir 58 calcineurin inhibitor 58 hypoparathyroidism 58 Acute Myeloid Leukaemia AML 58 carcinoid tumors 58 riociguat 58 β blockers 58 Topical corticosteroids 58 peginterferon alfa 2a 58 orchitis 58 late onset Pompe 58 romiplostim 58 stage IIIb 58 refractory CML 58 xanthine oxidase inhibitor 58 amoxicillin clavulanate 58 macroalbuminuria 58 Zavesca ® 58 colorectal cancer liver metastases 58 PCNSL 58 acetonide FA 58 low dose cytarabine 58 rapid virologic response 58 oral ridaforolimus 58 BRAF V#E mutation 58 nucleoside naive 58 EGFR mutations 58 HuMax CD4 58 Zolinza 58 Amrubicin 58 idiopathic thrombocytopenic purpura ITP 58 tuberous sclerosis TS 58 HCD# [002] 58 curative resection 58 CAELYX 58 heavily pretreated patients 58 hypercholesterolemic patients 58 FVIII inhibitors 58 pT2 58 abnormal Pap smears 58 Cimzia TM 58 intravesical therapy 58 interferon 58 enterococcal 58 huC# DM4 58 GW# [003] 58 dosing cohort 58 boosted protease inhibitor 58 Elitek 58 Thiovir 58 Vidaza ® 58 paclitaxel carboplatin 58 recurrent GBM 58 Asentar 58 refractory Hodgkin 58 VELCADE melphalan 58 nonmetastatic 58 nonnucleoside reverse transcriptase inhibitors 58 Irinotecan 58 immunosuppressive agents 58 Rheumatoid Arthritis RA 58 Vidaza azacitidine 58 lipohypertrophy 58 corticosteroid therapy 58 daunorubicin 58 advanced NSCLC 58 MGd 58 kidney urologic 58 stage IIIb IV 58 dalteparin 58 zidovudine AZT 58 severe sepsis 58 Candida infection 58 alpha 2a 58 Ribavirin 58 receiving VICTRELIS 58 Cancidas 58 NRTIs 58 co trimoxazole 58 RAS mutations 58 relapsing remitting multiple sclerosis 58 chlorambucil 58 reslizumab 58 ALN TTR 58 ganciclovir 58 cervical intraepithelial neoplasia 58 achieved sustained virologic 58 lesinurad 58 ancrod 58 severely immunocompromised 58 vidofludimus 58 VP# [004] 58 anal HPV 58 CIMZIA TM 58 GIST tumors 58 4mg/kg 58 adecatumumab 58 KETEK 58 biochemical relapse 58 primary hypercholesterolemia 58 FTC TDF 58 ELACYT 58 systemic corticosteroids 58 alefacept 58 Panzem R NCD 58 systemic lupus erythematosus 58 ertapenem 58 metastatic GIST 58 concurrent chemoradiation 58 pneumococcal pneumonia 58 EndoTAGTM 1 58 relapsed refractory 58 chemoradiation therapy 58 pulmonary hypertension PH 58 irinotecan chemotherapy 58 dexrazoxane 58 Gorlin syndrome 58 acyclovir Lauriad R 58 neutropenia dehydration dyspnea 58 randomized #:# 58 MDR tuberculosis 58 systemic lupus erythematosus SLE 58 inhaled liposomal ciprofloxacin 58 Severe VOD 58 dopamine partial agonist 58 Hepsera adefovir dipivoxil 58 TORISEL 58 elevated LDH 58 metastatic colorectal 58 alvespimycin 58 diagnosed GBM 58 Aptivus ® 58 MKC# MT 58 CEQ# 58 invasive fungal infections 58 lymphoid tumors 58 allogeneic stem cell 58 BEXXAR 58 ORENCIA ® 58 either acutely decompensated 58 eprotirome 58 Dasatinib 58 Arranon 58 HspE7 58 Pseudomonas aeruginosa infections 58 alkylating agents 58 mg q#h 58 GnRH agonist 58 plus ribavirin 58 alpha interferons 58 neovascular diseases 58 receptor blocker 58 ALN TTR# 58 paclitaxel Taxol R 58 allogeneic bone marrow 58 cervical dysplasia 58 Xyfid TM 58 PEG interferon 58 metastatic colorectal carcinoma 58 Cethromycin 58 standard chemotherapy regimens 58 atovaquone 58 transplantation HCT 58 oblimersen 58 Naive Patients 58 plasma uric acid 58 Bezielle 58 ACTEMRA TM 58 polycythemia vera essential thrombocythemia 58 gastric carcinoma 58 Glioblastoma Multiforme GBM 58 μg dose 58 LEXIVA r 58 Insegia 58 OvaRex ® MAb 58 Cutaneous T 58 rheumatoid arthritis psoriatic arthritis 58 genital ulcers 58 peptide antigens 58 taxotere 58 Clevudine 58 HBV 58 Lung transplantation 58 acute coronary syndromes ACS 58 peginterferon alfa 2a Pegasys 58 pharmacokinetic interactions 58 clodronate 58 pegylated liposomal doxorubicin 58 prior chemotherapy regimens 58 predictive biomarkers 58 chronic ITP 58 fluoropyrimidine 58 histologically proven 58 hyperplasia BPH 58 SSc 58 carboplatin paclitaxel 58 rituximab Rituxan 58 B CLL 58 Flu Cy 58 smoldering myeloma 58 Carcinoid tumors 58 Dacogen decitabine 58 poor metabolizers 58 elevated serum creatinine 58 ErbB2 positive 58 INVEGA ® 58 oral diclofenac 58 forodesine hydrochloride 58 premalignant 58 CC genotype 58 blinded randomized placebo controlled 58 virus HCV 58 neovascular form 58 seroprotection 58 potentially hepatotoxic 58 STELARA TM 58 prostate adenocarcinoma 58 Adjunctive 58 Zerenex 58 Onychomycosis 58 diabetic neuropathic pain 58 proliferative retinopathy 58 squamous cell histology 58 ara C 58 chronic immune thrombocytopenic 58 virological failure 58 rFVIIa 58 imatinib mesylate Gleevec 58 geographic atrophy 58 peritoneal carcinomatosis 58 Renal Cell Carcinoma RCC 58 TTR amyloidosis 58 efavirenz EFV 58 YONDELIS 58 cytarabine daunorubicin 58 Adjuvant chemotherapy 58 overt nephropathy 58 MabThera Rituxan 58 phase IIb clinical 58 antiviral therapy 58 EOquin 58 ADPKD 58 SinuNase TM 58 locoregional recurrence 58 sunitinib malate 58 thrombocytopenic patients 58 PEGINTRON TM 58 pT3 58 arterial thrombosis 58 MyVax R 58 Vicinium TM 58 Orally administered 58 adalimumab 58 peg IFN 58 TELINTRA 58 granulomatous 58 oral antidiabetic agents 58 chronic myeloid 58 nab paclitaxel 58 palliative radiotherapy 58 seroconverted 58 achieved sustained virological 58 commercialize deforolimus 58 type 1diabetes 58 prokinetic agent 58 AKT inhibitor 58 Voreloxin 58 Hepatitis C Virus 58 asymptomatic 58 locoregional 58 serum urate levels 58 heterozygous FH 58 Topotecan 58 Waldenstrom macroglobulinemia 58 mutated KRAS gene 58 anaplastic 58 ß blockers 58 BCR ABL inhibitor 58 FASLODEX 58 palifermin 58 prophylactic therapy 58 oral methylnaltrexone 58 goserelin 58 pentamidine 58 lichen planus 58 psoriasis vulgaris 58 hyperuricemia 58 gatifloxacin 58 Bendamustine 58 Allovectin 7 58 secondary hyperparathyroidism SHPT 58 pyridostigmine 58 migalastat HCl 58 Temsirolimus 58 aHUS 58 mCRC patients 58 beta interferons 58 underwent surgical resection 58 Kit CD# positive 58 hyperphosphataemia 58 hormone refractory prostate cancer 58 basiliximab 58 complement inhibitor eculizumab 58 mixed dyslipidemia 57 DCVax ® Brain 57 nevirapine Viramune 57 highly immunogenic 57 Clostridium difficile associated 57 acute decompensated heart 57 trimethoprim sulfamethoxazole 57 trabectedin